share_log

HC Wainwright & Co. Initiates Coverage On Structure Therapeutics With Buy Rating, Announces Price Target of $80

HC Wainwright & Co. Initiates Coverage On Structure Therapeutics With Buy Rating, Announces Price Target of $80

HC Wainwright & Co. 開始對Structure Therapeutics進行覆蓋,給予買入評級,並宣佈目標價格爲80美元。
Benzinga ·  2024/12/04 05:30  · 評級/大行評級

HC Wainwright & Co. analyst Andrew Fein initiates coverage on Structure Therapeutics (NASDAQ:GPCR) with a Buy rating and announces Price Target of $80.

HC Wainwright & Co. 分析師 Andrew Fein 給Structure Therapeutics(納斯達克:GPCR)初始了買入評級,並宣佈目標價格爲$80。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論